Drug Type Small molecule drug |
Synonyms Enarodustat (JAN), 恩那度司他 + [4] |
Target |
Mechanism HIF-PHs inhibitors(Hypoxia-inducible factor prolyl hydroxylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (25 Sep 2020), |
Regulation- |
Molecular FormulaC17H16N4O4 |
InChIKeyNALAUGMPMIVAOW-UHFFFAOYSA-N |
CAS Registry1262132-81-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
chronic renal failure anemia | KR | 17 Nov 2022 | |
Anemia of renal disease | JP | 25 Sep 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
chronic renal failure anemia | Phase 3 | CN | 09 Dec 2020 | |
Anemia in chronic kidney disease | Phase 1 | US | 01 May 2013 | |
Kidney Failure, Chronic | Phase 1 | US | 01 May 2013 |
Not Applicable | Anemia in chronic kidney disease hemoglobin | erythropoietin | 22 | (nyjgnbpvrp) = The results of reticulocyte count, hematocrit level and red blood cells in terms of changes from baseline at Week 6 were similar to that in hemoglobin qkidceugbi (bqgksxpxvv ) View more | Positive | 21 May 2015 |